{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T22:50:43Z","timestamp":1788648643770,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T00:00:00Z","timestamp":1708905600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018623","name":"Quanzhou City Science and Technology Program","doi-asserted-by":"publisher","award":["2019N027S"],"award-info":[{"award-number":["2019N027S"]}],"id":[{"id":"10.13039\/501100018623","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.heliyon.2024.e27147","type":"journal-article","created":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T23:35:23Z","timestamp":1708990523000},"page":"e27147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["FOXM1 promotes the progression of non-small cell lung cancer by inhibiting miR-509-5p expression via binding to the miR-509-5p promoter region"],"prefix":"10.1016","volume":"10","author":[{"given":"Mengcha","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2024.e27147_bib1","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/s41379-021-00987-4","article-title":"Deep convolutional neural network-based classification of cancer cells on cytological pleural effusion images","volume":"35","author":"Xie","year":"2022","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.heliyon.2024.e27147_bib2","article-title":"Efficacy and safety of Anti-PD-1 Plus Anlotinib in patients with advanced non-small-cell lung cancer after previous systemic treatment failure-a retrospective study","volume":"11","author":"Wang","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.heliyon.2024.e27147_bib3","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.21037\/apm-21-321","article-title":"Successful treatment using targeted therapy, radiotherapy, and intrathecal chemotherapy in a patient with leptomeningeal metastasis with an epidermal growth factor receptor exon 20 insertion mutation: a case report","volume":"11","author":"Ma","year":"2022","journal-title":"Ann. Palliat. Med."},{"key":"10.1016\/j.heliyon.2024.e27147_bib4","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1080\/14737140.2022.2102483","article-title":"Clinically-meaningful improvements in therapy for unresectable NSCLC","volume":"22","author":"Katakura","year":"2022","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.heliyon.2024.e27147_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e11081","article-title":"Cell cycle associated miRNAs as target and therapeutics in lung cancer treatment","volume":"8","author":"Fariha","year":"2022","journal-title":"Heliyon"},{"key":"10.1016\/j.heliyon.2024.e27147_bib6","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1634\/theoncologist.2018-0296","article-title":"Adverse event management in patients with BRAF V600E-mutant non-small cell lung cancer treated with Dabrafenib plus Trametinib","volume":"24","author":"Chalmers","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.heliyon.2024.e27147_bib7","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12964-018-0266-6","article-title":"Regulation of the master regulator FOXM1 in cancer","volume":"16","author":"Liao","year":"2018","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.heliyon.2024.e27147_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2021.e06846","article-title":"FOXM1c is the predominant FOXM1 isoform expressed in cholangiocarcinoma that associated with metastatic potential and poor prognosis of patients","volume":"7","author":"Klinhom-On","year":"2021","journal-title":"Heliyon"},{"key":"10.1016\/j.heliyon.2024.e27147_bib9","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1158\/0008-5472.CAN-05-3003","article-title":"The Forkhead Box m1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer","volume":"66","author":"Kim","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e27147_bib10","article-title":"FOXM1 Inhibition enhances the therapeutic outcome of lung cancer immunotherapy by modulating PD-L1 expression and cell proliferation","volume":"9","author":"Madhi","year":"2022","journal-title":"Adv. Sci."},{"key":"10.1016\/j.heliyon.2024.e27147_bib11","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.lungcan.2012.10.019","article-title":"FoxM1 expression is significantly associated with cisplatin-based chemotherapy resistance and poor prognosis in advanced non-small cell lung cancer patients","volume":"79","author":"Wang","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.heliyon.2024.e27147_bib12","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ccr.2011.10.003","article-title":"Location, location, location: FoxM1 mediates \u03b2-catenin nuclear translocation and promotes glioma tumorigenesis","volume":"20","author":"Bowman","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.heliyon.2024.e27147_bib13","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1111\/j.1349-7006.2010.01650.x","article-title":"Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis","volume":"101","author":"Kosaka","year":"2010","journal-title":"Cancer Sci."},{"key":"10.1016\/j.heliyon.2024.e27147_bib14","doi-asserted-by":"crossref","first-page":"314","DOI":"10.14348\/molcells.2014.2360","article-title":"Inhibition of cell proliferation and migration by miR-509-3p that targets CDK2, Rac1, and PIK3C2A","volume":"37","author":"Yoon","year":"2014","journal-title":"Mol. Cells"},{"key":"10.1016\/j.heliyon.2024.e27147_bib15","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s11845-013-0941-y","article-title":"Tumor suppressive miR-509-5p contributes to cell migration, proliferation and antiapoptosis in renal cell carcinoma","volume":"182","author":"Zhang","year":"2013","journal-title":"Ir. J. Med. Sci."},{"key":"10.1016\/j.heliyon.2024.e27147_bib16","doi-asserted-by":"crossref","first-page":"e1387","DOI":"10.1038\/cddis.2014.327","article-title":"Mir-509-5p joins the Mdm2\/p53 feedback loop and regulates cancer cell growth","volume":"5","author":"Ren","year":"2014","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.heliyon.2024.e27147_bib17","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.bbrc.2016.11.136","article-title":"MiR-509-5p suppresses the proliferation, migration, and invasion of non-small cell lung cancer by targeting YWHAG","volume":"482","author":"Wang","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.heliyon.2024.e27147_bib18","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1159\/000443086","article-title":"The tumor suppressive role of miRNA-509-5p by targeting FOXM1 in non-small cell lung cancer","volume":"38","author":"Ma","year":"2016","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.heliyon.2024.e27147_bib19","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.biopha.2017.04.001","article-title":"Baicalein increases cisplatin sensitivity of A549 lung adenocarcinoma cells via PI3K\/Akt\/NF-\u03baB pathway","volume":"90","author":"Yu","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.heliyon.2024.e27147_bib20","first-page":"483","article-title":"In vitro antitumor effect of cucurbitacin E on human lung cancer cell line and its molecular mechanism","volume":"18","author":"Jing","year":"2020","journal-title":"Chin. J. Nat. Med."},{"key":"10.1016\/j.heliyon.2024.e27147_bib21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.gene.2015.07.034","article-title":"Direct transfection of miR-137 mimics is more effective than DNA demethylation of miR-137 promoter to augment anti-tumor mechanisms of delphinidin in human glioblastoma U87MG and LN18 cells","volume":"573","author":"Chakrabarti","year":"2015","journal-title":"Gene"},{"key":"10.1016\/j.heliyon.2024.e27147_bib22","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13046-019-1093-3","article-title":"Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2\/STAT3\/VEGFA signaling in non-small cell lung cancer cells","volume":"38","author":"Liang","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e27147_bib23","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1038\/ncomms6165","article-title":"Suppression of the FOXM1 transcriptional programme via novel small molecule inhibition","volume":"5","author":"Gormally","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.heliyon.2024.e27147_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2022.115095","article-title":"Cinobufagin induces FOXO1-regulated apoptosis, proliferation, migration, and invasion by inhibiting G9a in non-small-cell lung cancer A549 cells","volume":"291","author":"Zhang","year":"2022","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.heliyon.2024.e27147_bib25","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s12931-020-01477-y","article-title":"FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer","volume":"21","author":"Sun","year":"2020","journal-title":"Respir. Res."},{"key":"10.1016\/j.heliyon.2024.e27147_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.scitotenv.2019.134122","article-title":"Cell metabolomics to study the cytotoxicity of carbon black nanoparticles on A549 cells using UHPLC-Q\/TOF-MS and multivariate data analysis","volume":"698","author":"Hou","year":"2020","journal-title":"Sci. Total Environ."},{"key":"10.1016\/j.heliyon.2024.e27147_bib27","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jflm.2016.08.015","article-title":"RNA degradation as described by a mathematical model for postmortem interval determination","volume":"44","author":"Lv","year":"2016","journal-title":"J. Forensic Leg. Med."},{"key":"10.1016\/j.heliyon.2024.e27147_bib28","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3892\/mmr.2021.11996","article-title":"miR-320a-3P alleviates the epithelial-mesenchymal transition of A549 cells by activation of STAT3\/SMAD3 signaling in a pulmonary fibrosis model","volume":"23","author":"Wang","year":"2021","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.heliyon.2024.e27147_bib29","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.2147\/OTT.S233129","article-title":"Epigenetic mechanism of enrichment of A549 lung cancer stem cells with 5-Fu","volume":"14","author":"Cao","year":"2021","journal-title":"OncoTargets Ther."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024031785?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024031785?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:35:08Z","timestamp":1761784508000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024031785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2405844024031785"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e27147","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FOXM1 promotes the progression of non-small cell lung cancer by inhibiting miR-509-5p expression via binding to the miR-509-5p promoter region","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e27147","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e27147"}}